These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10827390)

  • 1. Safety assessment of perflenapent emulsion for echocardiographic contrast enhancement in patients with congestive heart failure or chronic obstructive pulmonary disease.
    Kitzman DW; Wesley DJ
    Am Heart J; 2000 Jun; 139(6):1077-80. PubMed ID: 10827390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety assessment of the use of perflenapent emulsion for contrast enhancement of echocardiography and diagnostic radiology ultrasound studies.
    Quay SC; Eisenfeld AJ
    Clin Cardiol; 1997 Oct; 20(10 Suppl 1):I19-26. PubMed ID: 9383598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perflenapent emulsion: a US contrast agent for diagnostic radiology--multicenter, double-blind comparison with a placebo. EchoGen Contrast Ultrasound Study Group.
    Robbin ML; Eisenfeld AJ
    Radiology; 1998 Jun; 207(3):717-22. PubMed ID: 9609895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The improvement of echocardiographic assessment of the left ventricle by the use of perflenapent and harmonic imaging].
    Olszewski R; Marciniak W; Nowicki A; Gil M; Etienne J; Karłowicz P; Adamus J
    Pol Merkur Lekarski; 1998 Sep; 5(27):132-4. PubMed ID: 10101477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perflenapent emulsion (EchoGen): a new long-acting phase-shift agent for contrast echocardiography.
    Grayburn P
    Clin Cardiol; 1997 Oct; 20(10 Suppl 1):I12-8. PubMed ID: 9383597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying principles of pharmacoeconomic evaluation to perflenapent emulsion, a new echocardiographic contrast agent for use in cardiac function testing.
    Wellman G; Sherrin T
    Clin Ther; 1997; 19(4):837-46. PubMed ID: 9377626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images.
    Kitzman DW; Goldman ME; Gillam LD; Cohen JL; Aurigemma GP; Gottdiener JS
    Am J Cardiol; 2000 Sep; 86(6):669-74. PubMed ID: 10980221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent. Results of a phase III Multicenter Trial.
    Cohen JL; Cheirif J; Segar DS; Gillam LD; Gottdiener JS; Hausnerova E; Bruns DE
    J Am Coll Cardiol; 1998 Sep; 32(3):746-52. PubMed ID: 9741522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III multicenter trial comparing the efficacy of 2% dodecafluoropentane emulsion (EchoGen) and sonicated 5% human albumin (Albunex) as ultrasound contrast agents in patients with suboptimal echocardiograms.
    Grayburn PA; Weiss JL; Hack TC; Klodas E; Raichlen JS; Vannan MA; Klein AL; Kitzman DW; Chrysant SG; Cohen JL; Abrahamson D; Foster E; Perez JE; Aurigemma GP; Panza JA; Picard MH; Byrd BF; Segar DS; Jacobson SA; Sahn DJ; DeMaria AN
    J Am Coll Cardiol; 1998 Jul; 32(1):230-6. PubMed ID: 9669275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive assessment of cardiac function during exercise in patients with CHF or COPD: measurement of aortic bloodflow indices by continuous wave Doppler.
    Hux JE; McCormack DG; Arnold JM
    Can J Cardiol; 1996 Jun; 12(6):587-92. PubMed ID: 8665421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent coexistence of chronic heart failure and chronic obstructive pulmonary disease in respiratory and cardiac outpatients: Evidence from SUSPIRIUM, a multicentre Italian survey.
    Griffo R; Spanevello A; Temporelli PL; Faggiano P; Carone M; Magni G; Ambrosino N; Tavazzi L;
    Eur J Prev Cardiol; 2017 Apr; 24(6):567-576. PubMed ID: 28067533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic markers for the development of adverse outcomes in patients with chronic obstructive pulmonary disease and chronic heart failure].
    Karoli NA; Borodkin AV; Kosheleva NA; Rebrov AP
    Kardiologiia; 2018 Sep; 58(Suppl 9):39-47. PubMed ID: 30312570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic effects of creatine phosphate in patients with congestive heart failure: a double-blind comparison trial versus placebo.
    Ferraro S; Codella C; Palumbo F; Desiderio A; Trimigliozzi P; Maddalena G; Chiariello M
    Clin Cardiol; 1996 Sep; 19(9):699-703. PubMed ID: 8874988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical safety of SonoVue, a new contrast agent for ultrasound imaging, in healthy volunteers and in patients with chronic obstructive pulmonary disease.
    Bokor D; Chambers JB; Rees PJ; Mant TG; Luzzani F; Spinazzi A
    Invest Radiol; 2001 Feb; 36(2):104-9. PubMed ID: 11224758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doppler sonographic enhancement of hepatic hemangiomas and hepatocellular carcinomas after perflenapent emulsion: preliminary study.
    Lopez-Ben R; Robbin ML; Weber TM; Smith JK; Needleman L; Berland LL
    J Ultrasound Med; 1999 Feb; 18(2):109-16. PubMed ID: 10206803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and significance of unrecognized chronic obstructive pulmonary disease in elderly patients with stable heart failure.
    Apostolovic S; Jankovic-Tomasevic R; Salinger-Martinovic S; Djordjevic-Radojkovic D; Stanojevic D; Pavlovic M; Stankovic I; Putnikovic B; Kafedzic S; Catovic S; Tahirovic E; Düngen HD
    Aging Clin Exp Res; 2011; 23(5-6):337-42. PubMed ID: 20940533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. The Alprostadil Investigators.
    Reisin L; Marmor A; Rabinowitz B; Bernink PJ; Caspi A; Ruzyllo W; Borer JS
    Am J Ther; 1997; 4(11-12):365-74. PubMed ID: 10423632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.
    Lainscak M; Podbregar M; Kovacic D; Rozman J; von Haehling S
    Respir Med; 2011 Oct; 105 Suppl 1():S44-9. PubMed ID: 22015086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opacification and border delineation improvement in patients with suboptimal endocardial border definition in routine echocardiography: results of the Phase III Albunex Multicenter Trial.
    Crouse LJ; Cheirif J; Hanly DE; Kisslo JA; Labovitz AJ; Raichlen JS; Schutz RW; Shah PM; Smith MD
    J Am Coll Cardiol; 1993 Nov; 22(5):1494-500. PubMed ID: 8227810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.